Kymera Therapeutics

$33.77 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest


About Kymera Therapeutics

Kymera Therapeutics Inc is a biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. Its targeted protein degradation platform, Pegasus, allows it to discover selective small molecule protein degraders with potent activity against disease-causing proteins throughout the body. Its initial programs include IRAK4, IRAKIMiD, and STAT3. The Company is developing its IRAK4 program for the treatment of a broad set of immunology-inflammation diseases, including hidradenitis suppurativa (HS), atopic dermatitis (AD) and rheumatoid. Its programs are focused on a single critical signaling node within the genetically and clinically validated IL-1R/TLR and JAK/STAT pathways.

Stock Analysis

last close $33.77
1-mo return 47.9%
3-mo return 99.8%
avg daily vol. 696.09T
52-week high 69.12
52-week low 13.15
market cap. $1.6B
forward pe -
annual div. -
roe -35.2%
ltg forecast -
dividend yield -
annual rev. $64M
inst own. 97.8%

Subscribe now for daily local and international financial news